Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Apr 12

PMID 35406576

Authors

Khalil Saleh

Alexis Fernandez

Florence Pasquier

Affiliations

Soon will be listed here.

Abstract

Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) is the most common subtype of B-ALL in adults and its incidence increases with age. It is characterized by the presence of BCR-ABL oncoprotein that plays a central role in the leukemogenesis of Ph+ ALL. Ph+ ALL patients traditionally had dismal prognosis and long-term survivors were only observed among patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first complete remission (CR1). However, feasibility of allo-HSCT is limited in this elderly population. Fortunately, development of increasingly powerful tyrosine kinase inhibitors (TKIs) from the beginning of the 2000's dramatically improved the prognosis of Ph+ ALL patients with complete response rates above 90%, deep molecular responses and prolonged survival, altogether with good tolerance. TKIs became the keystone of Ph+ ALL management and their great efficacy led to develop reduced-intensity chemotherapy backbones. Subsequent introduction of blinatumomab allowed going further with development of chemo free strategies. This review will focus on these amazing recent advances as well as novel therapeutic strategies in adult Ph+ ALL.

Citing Articles

Flow cytometric characterisation of acute leukaemia in adolescent and adult Ethiopians.

Alemu J, Gumi B, Tsegaye A, Sherif A, Tadesse F, Gebremedhin A Afr J Lab Med. 2025; 14(1):2394.

PMID: 39968161 PMC: 11830883. DOI: 10.4102/ajlm.v14i1.2394.

Ponatinib as a Prophylactic or Pre-Emptive Strategy to Prevent Cytological Relapse after Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Transplanted in Complete Cytological....

Candoni A, Chiusolo P, Lazzarotto D, Sartor C, DArgenio M, Chiaretti S Cancers (Basel). 2024; 16(11).

PMID: 38893226 PMC: 11171293. DOI: 10.3390/cancers16112108.

MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical Implications.

Tran V, Salafian K, Michaels K, Jones C, Reed D, Keng M Curr Hematol Malig Rep. 2024; 19(4):186-196.

PMID: 38888822 PMC: 11316691. DOI: 10.1007/s11899-024-00736-9.

Asciminib stands out as the superior tyrosine kinase inhibitor to combine with anti-CD20 monoclonal antibodies for the treatment of CD20 Philadelphia-positive B-cell precursor acute lymphoblastic leukemia in preclinical models.

Domka K, Dabkowska A, Janowska M, Urbanska Z, Pastorczak A, Winiarska M Haematologica. 2024; 109(11):3520-3532.

PMID: 38841802 PMC: 11532687. DOI: 10.3324/haematol.2023.284853.

Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.

Zhao Y, Laird A, Roberts K, Yafawi R, Kantarjian H, DeAngelo D Blood Adv. 2024; 8(12):3226-3236.

PMID: 38607410 PMC: 11225676. DOI: 10.1182/bloodadvances.2023012430.

References

Corbacioglu S, Jabbour E, Mohty M . Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome. Biol Blood Marrow Transplant. 2019; 25(7):1271-1280. DOI: 10.1016/j.bbmt.2019.02.018. View

Chiaretti S, Ansuinelli M, Vitale A, Elia L, Matarazzo M, Piciocchi A . A multicenter total therapy strategy for adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol. Haematologica. 2021; 106(7):1828-1838. PMC: 8252956. DOI: 10.3324/haematol.2020.260935. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Foa R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris M . Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011; 118(25):6521-8. DOI: 10.1182/blood-2011-05-351403. View

Rousselot P, Coude M, Gokbuget N, Passerini C, Hayette S, Cayuela J . Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016; 128(6):774-82. PMC: 5085255. DOI: 10.1182/blood-2016-02-700153. View

Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A . Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006; 12(24):7374-9. DOI: 10.1158/1078-0432.CCR-06-1516. View

Fielding A, Richards S, Chopra R, Lazarus H, Litzow M, Buck G . Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2006; 109(3):944-50. DOI: 10.1182/blood-2006-05-018192. View

Porkka K, Koskenvesa P, Lundan T, Rimpilainen J, Mustjoki S, Smykla R . Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008; 112(4):1005-12. DOI: 10.1182/blood-2008-02-140665. View

Rea D, Mauro M, Boquimpani C, Minami Y, Lomaia E, Voloshin S . A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021; 138(21):2031-2041. PMC: 9728405. DOI: 10.1182/blood.2020009984. View

10.

Tanguy-Schmidt A, Rousselot P, Chalandon Y, Cayuela J, Hayette S, Vekemans M . Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. Biol Blood Marrow Transplant. 2012; 19(1):150-5. DOI: 10.1016/j.bbmt.2012.08.021. View

11.

Dhedin N, Dombret H, Thomas X, Lheritier V, Boiron J, Rigal-Huguet F . Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials. Leukemia. 2005; 20(2):336-44. DOI: 10.1038/sj.leu.2404065. View

12.

Hirschbuhl K, Labopin M, Houhou M, Gabellier L, Labussiere-Wallet H, Lioure B . Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party. Bone Marrow Transplant. 2020; 56(5):1190-1199. DOI: 10.1038/s41409-020-01173-x. View

13.

Giebel S, Czyz A, Ottmann O, Baron F, Brissot E, Ciceri F . Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party.... Cancer. 2016; 122(19):2941-51. DOI: 10.1002/cncr.30130. View

14.

Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F . Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche.... Blood. 2007; 109(9):3676-8. DOI: 10.1182/blood-2006-10-052746. View

15.

Dombret H, Gabert J, Boiron J, Rigal-Huguet F, Blaise D, Thomas X . Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial. Blood. 2002; 100(7):2357-66. DOI: 10.1182/blood-2002-03-0704. View

16.

Ram R, Storb R, Sandmaier B, Maloney D, Woolfrey A, Flowers M . Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica. 2011; 96(8):1113-20. PMC: 3148904. DOI: 10.3324/haematol.2011.040261. View

17.

King A, Pappacena J, Tallman M, Park J, Geyer M . Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia. Leuk Res. 2019; 79:27-33. PMC: 7536787. DOI: 10.1016/j.leukres.2019.02.009. View

18.

Gu B, Shi B, Zhang X, Zhou S, Chu J, Wu X . Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cells. Bone Marrow Transplant. 2020; 56(1):91-100. DOI: 10.1038/s41409-020-0982-6. View

19.

Kantarjian H, Stein A, Gokbuget N, Fielding A, Schuh A, Ribera J . Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017; 376(9):836-847. PMC: 5881572. DOI: 10.1056/NEJMoa1609783. View

20.

Kebriaei P, Cutler C, de Lima M, Giralt S, Lee S, Marks D . Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018; 53(4):449-456. PMC: 5897380. DOI: 10.1038/s41409-017-0019-y. View